Because AEs lead to permanent treatment discontinuation could reduce the efficacy of anti-HER2 treatment in breast cancer, thus clinicians should pay more attention to severe toxicities with anti-HER2 treatment. The gene discussed is ERBB2; the disease is breast carcinoma.